biochemical failure

biochemical failure

asymptomatic disease recurrence marked only by variance in values determined on clinical laboratory monitoring.
Farlex Partner Medical Dictionary © Farlex 2012

biochemical failure

An oncology term of art referring to an increase in PSA after what was thought to be definitive therapy for prostate cancer, which is usually an indicator of local or metastatic disease progression.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
Long-Term Hazard of Progression After Radical Prostatectomy For Clinically Localized Prostate Cancer: Continued Risk of Biochemical Failure After 5 Years.
In 2011, Iczkowski et al (36) demonstrated that the presence of cribriform pattern was an independent risk factor significantly associated with biochemical failure after radical prostatectomy in 153 patients studied, and the risk was similar to that for tumors with infiltrating GP 5 in a subset of patients.
"Despite improvements in biochemical failure and distant metastases, dose escalation did not improve OS," the authors write.
In this issue of CUAJ, Ajib et al present data showcasing oncological and functional outcomes after salvage radiation (SRT) for biochemical failure for prostate cancer treated with robot-assisted radical prostatectomy (RARP).
After 16 cycles of docetaxel, the patient presented with biochemical failure, indicated by an elevated PSA level of 40.2 ng/ml.
Levy and other Cleveland Clinic researchers indicate that 29 percent of men who fail to achieve a PSA nadir of less than 0.4 ng/mL after cryosurgery will experience biochemical failure (a rise in PSA levels suggestive of prostate cancer recurrence) within 24 months of the procedure.
31 January 2014 - US genomic tests provider GenomeDx Biosciences announced yesterday new data indicating that its Decipher prostate cancer classifier, which measures the biological risk of metastatic prostate cancer, outperformed existing clinical risk factors for predicting biochemical failure and distant metastasis following radiation therapy
The maintenance of a PSA < 0.5 ng/mL was noted in 50% (36/72) of these patients at 10 years of follow-up; only 12.5% (9/72) of these patients experienced biochemical failure according to the Phoenix criteria during the follow-up.
For prognostic monitoring, the elevation of prostate-specific antigen (PSA) concentration in blood after prostatectomy (called biochemical failure, or biochemical relapse) remains the only available marker (1).
James Jensen, Department of Surgery--"Feasibility and Safety of Nutritional Supplementation with Omega-3 Fatty Acids to Reduce Prostate Specific Antigen Rise in Men with Biochemical Failure after Prostatectomy or External-Beam Radiotherapy"
Nor were there differences in biochemical failure, regional or distant recurrence, pelvic metastases, or the need for a second course of androgen blockade.
Since the publication of Huggins work in 1942 [1], androgen blockade has been a treatment option for metastastic prostate cancer and for biochemical failure after primary therapy.